Frankfurt - Delayed Quote EUR

Faron Pharmaceuticals Oy (4FR.F)

2.4000

-0.0650

(-2.64%)

As of 8:05:16 AM GMT+2. Market Open.

Faron Announces Acceptance of Bexmarilimab Phase II Data for Oral Presentation at ASCO 2025

Data from the BEXMAB study marks a significant milestone for next-generation cancer immunotherapies TURKU, FI / ACCESS Newswire / April 24, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN), a clinical-stage biopharmaceutical company developing novel immunotherapies, ...

ACCESS Newswire 8 hours ago

FARN.L

FARON.HE
Holding in Company

TURKU, FI / ACCESS Newswire / April 17, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON)(HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces that, on 16 April 2025, ...

ACCESS Newswire 7 days ago

FARON.HE

FARN.L
Inside Information: Faron Announces Positive Phase II Results in Higher-risk Myelodysplastic Syndrome

TURKU, FI / ACCESS Newswire / April 15, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Inside Information: BEXMAB Phase II trial met its primary endpoint in treatment-resistant High Risk MDS (r/r HR MDS) Key Highlights Topline read-out from ...

ACCESS Newswire 9 days ago

FARON.HE

FARN.L
Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at 2025 Annual MDS Foundation Congress

TURKU, FI / ACCESS Newswire / March 27, 2025 /Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) New analysis and biomarker data strengthens understanding of bexmarilimab's potential TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), ...

ACCESS Newswire 28 days ago

FARN.L

FARON.HE
Board Changes

TURKU, FINLAND / ACCESS Newswire / March 21, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)(AIM: FARN) (First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor ...

ACCESS Newswire last month

FARON.HE

FARN.L
Results of the Annual General Meeting, Change of Directors, Decision of the Board Meeting After the AGM

TURKU, FI / ACCESS Newswire / March 21, 2025 /Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) Results of the Annual General Meeting, Change of Directors, Decision of the Board meeting after the AGM TURKU, FINLAND - The annual general meeting ("AGM") of ...

ACCESS Newswire last month

FARON.HE

FARN.L
Shareholders’ Nomination Board updates its Recommendation on the Number of Board Members to be Elected and the Persons Proposed to be Elected

TURKU, FI / ACCESS Newswire / March 20, 2025 /Faron Pharmaceuticals (HEL:FARON)(AIM:FARN) Shareholders' Nomination Board updates its recommendation on the number of Board members to be elected and the persons proposed to be elected Faron Pharmaceuticals ...

ACCESS Newswire last month

FARON.HE

FARN.L
Faron Pharmaceuticals Oy (FRA:4FR) Full Year 2024 Earnings Call Highlights: Financial Gains and ...

Faron Pharmaceuticals Oy (FRA:4FR) reports improved cash position and reduced losses, while navigating regulatory and commercialization hurdles.

GuruFocus.com last month

^YH206
Faron presents BEXMAB data at ASH Annual Meeting

Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announced full analysis of the positive Phase 2 interim readout presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition.

PR Newswire 4 months ago

FARN.L
Faron Pharma secures UK innovation passport for blood cancer immunotherapy

The MHRA has also granted approval to Faron Pharmaceuticals to conduct the BEXMAB trial of Clevegen in the UK.

Pharmaceutical Technology 4 months ago

^YH206

GLDAF
Faron Pharmaceuticals reports positive data from MDS trial

The combination treatment was found to be well tolerated without demonstrating any dose-limiting toxicity.

Clinical Trials Arena 10 months ago

^YH206
Faron Founders and bexmarilimab Developers Selected as Finalists for the European Inventor Award 2024

Dr. Markku Jalkanen and Dr. Sirpa Jalkanen, Faron’s co-founders, have been nominated as one of three finalists in the ‘SMEs’ category of prestigious European Patent Office AwardsNominated in recognition of research developing bexmarilimab, an investigational immunotherapy optimising clinical outcomes in cancer treatmentVoting now open for “Popular Prize” award ahead of ceremony on July 9 via dedicated link: Sirpa Jalkanen and Markku Jalkanen | Epo.org TURKU, Finland and BOSTON, May 16, 2024 (GLO

GlobeNewswire 11 months ago

FARON.HE

FARN.L

Performance Overview

Return	4FR.F	FTSE 100 (^FTSE)
YTD	-2.44%	+2.53%
1-Year	+57.89%	+4.22%
3-Year	+81.82%	+11.41%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Faron Pharmaceuticals Oy (4FR.F)

Faron Announces Acceptance of Bexmarilimab Phase II Data for Oral Presentation at ASCO 2025

Holding in Company

Inside Information: Faron Announces Positive Phase II Results in Higher-risk Myelodysplastic Syndrome

Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at 2025 Annual MDS Foundation Congress

Board Changes

Results of the Annual General Meeting, Change of Directors, Decision of the Board Meeting After the AGM

Shareholders’ Nomination Board updates its Recommendation on the Number of Board Members to be Elected and the Persons Proposed to be Elected

Faron Pharmaceuticals Oy (FRA:4FR) Full Year 2024 Earnings Call Highlights: Financial Gains and ...

Faron presents BEXMAB data at ASH Annual Meeting

Faron Pharma secures UK innovation passport for blood cancer immunotherapy

Faron Pharmaceuticals reports positive data from MDS trial

Faron Founders and bexmarilimab Developers Selected as Finalists for the European Inventor Award 2024

Performance Overview